April 4, 2014 This puppy is a Nova Scotia Duck Tolling Retriever, the breed with the newly discovered genetic mutation for cleft palate. (Danika Bannasch/UC Davis) UC Davis School of Veterinary Medicine researchers have identified the genetic mutation responsible for a form of cleft palate in the dog breed Nova Scotia Duck Tolling Retrievers.
PUBLIC RELEASE DATE: 4-Apr-2014 Contact: Allison Hydzik email@example.com 412-559-2431 University of Pittsburgh Schools of the Health Sciences SAN DIEGO, April 4, 2014 Genetic screening of cancer can help doctors customize treatments so that patients with melanoma have the best chance of beating it, according to the results of a clinical trial by researchers at the University of Pittsburgh Cancer Institute (UPCI), a partner with UPMC CancerCenter. The trial, funded by the National Institutes of Health (NIH), will be presented Monday at the American Association for Cancer Research (AACR) Annual Meeting 2014. It showed that the cancer immune therapy drug ipilimumab appears most likely to prevent recurrence in patients whose cancer shows high expression of immune-related genes.
Transgenomic, Inc. , a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, today announced an agreement with Raptor Pharmaceuticals Inc
Is there a genetic component of this disease? APFED's Webinar Series Presents… Answers from Experts Is there a genetic component of this disease? (1) Continue reading →
San Francisco, CA (PRWEB) April 02, 2014 CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on informing clinical decision-making in molecular medicine, and The Jackson Laboratory (JAX), an independent, nonprofit biomedical research institution with a staff of over 1,500 employees, today announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by JAX
Enabled Reduced Analysis Time Per Case, Improved Ability to Track & Query Identified Variants BOSTON and LEUVEN, Belgium – Cartagenia, the world leader in software-based workflow support for genetic variant assessment, lab reporting, and integration of diagnostic knowledge-bases, today announced that the Human Genetics Laboratory, part of the Munroe-Meyer Institute for Genetics and Rehabilitation (MMI) at the University of Nebraska Medical Center (UNMC), has selected the Cartagenia Bench platform genetics diagnostics solution for use at its healthcare laboratory. Cartagenia Bench is a cloud-based platform that allows genetics labs and clinicians to analyze, interpret, report, and share genomic variants in routine clinical diagnostics. Jennifer N
PUBLIC RELEASE DATE: 1-Apr-2014 Contact: Kathy Beal firstname.lastname@example.org 301-238-4582 American College of Medical Genetics Jun Shen, PhD was honored as the 2014 recipient of the ACMG Foundation/Signature Genomics from PerkinElmer, Inc. Travel Award at the American College of Medical Genetics and Genomics (ACMG) 2014 Annual Clinical Genetics Meeting in Nashville, TN. Dr
PUBLIC RELEASE DATE: 31-Mar-2014 Contact: Kimberley Wang email@example.com 65-660-11653 National University of Singapore A team of scientists from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore and National University Cancer Institute Singapore (NCIS), and their collaborators from the Cedars-Sinai Medical Centre, UCLA School of Medicine, demonstrated that a number of novel genetic defects are able to induce oesophageal cancer. The research group, led by Professor H. Phillip Koeffler, Senior Principal Investigator at CSI Singapore and Deputy Director of NCIS, has conducted a successful comprehensive genomic study of oesophageal squamous carcinoma, a type of very aggressive cancer prevalent in Singapore and Southeast Asia
Heart valve defects are a common cause of death in newborns. Scientists at the University of Bonn and the caesar research center have discovered “Creld1″ is a key gene for the development of heart valves in mice. The researchers were able to show that a similar Creld1 gene found in humans functions via the same signaling pathway as in the mouse.
PUBLIC RELEASE DATE: 31-Mar-2014 Contact: Robin Dutcher robin.Dutcher@hitchcock.org 603-653-9056 The Geisel School of Medicine at Dartmouth While patients diagnosed with bladder cancer usually face a favorable prognosis, many experience recurrence after treatment. Because frequent, painful screenings are needed to identify recurrences, the ablility to identify patients at high risk of recurrent cancer could help to improve quality of life for all bladder cancer patients. A new study published in BJU International, “Genetic polymorphisms modify bladder cancer recurrence and survival in a U.S.
IRVINE, CA and FULTON, MD (PRWEB) March 31, 2014 Proove Biosciences, the leading personalized pain medicine laboratory, is proud to announce its membership in the Personalized Medicine Coalition, a unique organization created to advance personalized medicine as a viable solution to the challenges of healthcare safety, efficiency, and cost.
Inova Translational Medicine Institute and Personalis, Inc. today announced a partnership to advance genomic medicine for Inovas patient population. Personalis will collaborate with Inova on whole genome analysis and interpretation for undiagnosed syndromes in an effort to provide patients and their families an answer for these difficult cases
BOSTON and LEUVEN, Belgium, March 26, 2014 /PRNewswire/ –Cartagenia, the world leader in software-based workflow support for genetic variant assessment, lab reporting, and integration of diagnostic knowledge-bases, today announced that the Human Genetics Laboratory, part of the Munroe-Meyer Institute for Genetics and Rehabilitation (MMI) at the University of Nebraska Medical Center (UNMC), has …
Released: 3/25/2014 4:05 PM EDT Source Newsroom: Mayo Clinic Contact Information Available for logged-in reporters only http://newsnetwork.mayoclinic.org/discussion/implications-of-patient-genomic-sequencing-at-acmg Newswise ROCHESTER, Minn. Researchers from the Mayo Clinic Center for Individualized Medicine will present results of three different studies evaluating implications and feasibility of genome sequencing at the ACMG Annual Clinical Genetics Meeting this week in Nashville, Tenn. Presenters are available for interviews at the conference or remote interviews by telephone
Lead researcher Dr Peter Taylor, from the University of Cardiff’s School of Medicine, said: “If other studies confirm our finding then there may be benefit in carrying out a genetic test for this gene variant in addition to the standard neonatal thyroid screening, which would identify children most at risk of developing low IQ. Around 4 per cent of the population have the gene variant coupled with a lower than normal thyroid hormone levels
.@fordschool – Shobita Parthasarathy: Comparative Politics of Health Care Commentary Shobita Parthasarathy talks about her upcoming book titled “Building Genetic Medicine Breast Cancer Technology and the Comparative Politics of Hea… By: Politics (1) Continue reading →
PUBLIC RELEASE DATE: 21-Mar-2014 Contact: John Ascenzi firstname.lastname@example.org 267-426-6055 Children’s Hospital of Philadelphia Long before next-generation sequencing technology ushered in today’s data-intensive era of human genome information, clinicians have been taking family histories by jotting down pedigrees: hand-drawn diagrams recording how diseases may recur across generations, and offering clues to inheritance patterns. Now healthcare providers can create those diagrams digitally on an iPad screen with a few finger taps, during a face-to-face encounter with an individual and his or her family